Ironwood Pharmaceuticals (IRWD) - FREE Research Report Roberts Bryan E who is Director at Ironwood Pharmaceuticals sold 823,350 shares at $12.71 on Jan. 13, 2014. Following this transaction, the Director owned 147,000 shares meaning that the stake was reduced by 84.85% with the 823,350-share transaction. The shares most recently traded at $12.22, down $0.49, or 4.05% since the insider transaction. The average volume for Ironwood Pharmaceuticals has been 981,900 shares per day over the past 30 days. Ironwood Pharmaceuticals has a market cap of $1.3 billion and is part of the health care sector and health services industry. Shares are up 6.8% year-to-date as of the close of trading on Monday. Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. Currently there are 4 analysts that rate Ironwood Pharmaceuticals a buy, 1 analyst rates it a sell, and 6 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on IRWD - FREE TheStreet Quant Ratings rates Ironwood Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full Ironwood Pharmaceuticals Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts